Pascal Soriot, AP

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

CSL Behring chief Paul Per­reault scored an un­usu­al coup last sum­mer when he added As­traZeneca CEO Pas­cal So­ri­ot to the board, via Zoom. It’s rare, to say the least, to see a Big Phar­ma CEO take any board post in an in­dus­try where in­ter­ests can si­mul­ta­ne­ous­ly con­nect and col­lide on mul­ti­ple lev­els of op­er­a­tions.

The tie set the stage for an im­por­tant man­u­fac­tur­ing con­nec­tion. The Aus­tralian phar­ma gi­ant agreed to sup­ply the coun­try with 10s of mil­lions of As­traZeneca’s Covid-19 vac­cine, once it pass­es reg­u­la­to­ry muster.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.